Cambium Bio Limited
CMB
Rang in aandelen
#32452
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Aandeelprijs
$0.31613178
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$9.30M
Verandering (1 dag)
-0.39%
Verandering (1 jaar)
5,893.70%
Land
AU
Handel Cambium Bio Limited (CMB)
Categorie
Healthcare
Koersgeschiedenis voor Cambium Bio Limited (CMB)
Hoogste slotkoers: $0.01 op 2024-05-01
Laagste slotkoers: $0.25 op 2013-09-01
Laagste slotkoers: $0.25 op 2013-09-01
Koersgeschiedenis van Cambium Bio Limited van 2013 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2024 | 119.50% |
| 2023 | -92.08% |
| 2022 | -41.49% |
| 2021 | -42.78% |
| 2020 | 56.83% |
| 2019 | -53.42% |
| 2018 | 31.72% |
| 2017 | -21.51% |
| 2016 | 74.18% |
| 2015 | -41.39% |
| 2014 | -67.54% |
| 2013 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
